Veracyte is initiating 2023 annual total revenue guidance of $325 million to $335 million, assuming currency rates as of February 22, 2023. This range includes mid-teens year-over-year growth of testing and product revenue, and a decline in Biopharmaceutical and other revenue for fiscal 2023 compared to fiscal 2022.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VCYT:
- Biotech Alert: Searches spiking for these stocks today
- Veracyte: Value of test for men with high risk prostate cancer validated
- ‘Stay Long and Strong’: Billionaire Ken Fisher Snaps Up These 2 ‘Strong Buy’ Stocks
- Veracyte to present multiple Decipher urologic testing abstracts at ASCO
- Veracyte: Data show Afirma testing may help patients with thyroid nodules care
